KSPM
Search
- Page Path
- HOME > Search
Perspective
- Polypharmacy and Therapeutic Inertia in Extreme Longevity: A Potential Clinical Ageism Scenario Secondary to Important Gaps in Clinical Evidence
- María Viviana Pantoja, Ivan David Lozada-Martinez
- J Prev Med Public Health. 2024;57(5):508-510. Published online September 27, 2024
- DOI: https://doi.org/10.3961/jpmph.24.364
- 1,578 View
- 173 Download
- 1 Web of Science
- 1 Crossref
-
Abstract
Summary
PDF - Population aging is a global health priority due to the dramatic increase in the proportion of older persons worldwide. It is also expected that both global life expectancy and disability-free life expectancy will increase, leading to a significant rise in the proportion of individuals with extreme longevity, such as non-agenarians and centenarians. The inaccuracy of clinical evidence on therapeutic interventions for this demographic could lead to biased decision-making, influenced by age-related beliefs or misperceptions about their therapeutic needs. This represents a potential clinical ageism scenario stemming from gaps in clinical evidence. Such biases can result in 2 significant issues that adversely affect the health status and prognosis of older persons: polypharmacy and therapeutic inertia. To date, documents on polypharmacy in non-agenarians and centenarians account for less than 0.35% of the overall available evidence on polypharmacy. Furthermore, evidence regarding therapeutic inertia is non-existent. The purpose of this letter is to discuss polypharmacy and therapeutic inertia as potential clinical ageism scenarios resulting from the clinical evidence gaps in extreme longevity.
-
SummaryKey Message
The inaccuracy of clinical evidence on therapeutic interventions for extreme longevity (nonagenarians and centenarians) could lead to biased decision-making, influenced by age-related beliefs or misperceptions about their therapeutic needs: polypharmacy and therapeutic inertia. To date, documents on polypharmacy in nonagenarians and centenarians account for less than 0.35% of the overall available evidence on polypharmacy. Furthermore, evidence regarding therapeutic inertia is non-existent. This letter discusses polypharmacy and therapeutic inertia as potential clinical ageism scenarios resulting from the clinical evidence gaps in extreme longevity.Citations
Citations to this article as recorded by
- Association between home care and health phenotype of centenarians: Is it a necessary new criterion in home health care?
Ivan David Lozada‐Martinez, Paula Andrea Correa‐Diaz, Jorge Luis Correa‐Rosales, Juan‐Manuel Anaya
Australasian Journal on Ageing.2025;[Epub] CrossRef
First
Prev
